Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg

IBRO Neuroscience Reports(2022)10.1016/j.ibneur.2022.01.006Source: DataRank Database

The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg is a research paper published in IBRO Neuroscience Reports (2022). On theSindex it has a DataRank of 0. It has been cited 10 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access10 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 1.64)OA: goldTopics (43)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (11)

Andrew J. Roebuck ORCID,Quentin Greba,Sumanta Garai ORCID,Asher L. Brandt,Orhan Yılmaz ORCID

Live enrichment

PubMed:35128516 PMC:PMC8804275 OpenAlex:https://openalex.org/W4207025399

National Institutes of Health

Grant: 10677

National Institutes of Health

Grant: EY024717

National Institutes of Health

Grant: 5R01EY024717-03

A Novel Pharmacotherapy for Glaucoma

Canadian Institutes of Health Research

Grant: unidentified

unidentified

GlaxoSmithKline

Canadian Institutes of Health Research

Saskatchewan Health Research Foundation

FWCI

1.64

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

goldLicense: cc-by-nc-nd

journalhttps://www.sciencedirect.com/science/article/pii/S2667242122000069/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S2667242122000069/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2667242122000069?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2667242122000069?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ibneur.2022.01.006

Fields of Study

Cannabis and Cannabinoid ResearchNeuroscience and Neuropharmacology ResearchSleep and Wakefulness Research03 medical and health sciences0302 clinical medicine

Keywords

EpilepsyAllosteric regulationAllosteric modulatorSpike-and-wavePharmacologySeizure thresholdAnticonvulsantElectroencephalographyAdverse effectMedicineDrug Resistant EpilepsyCannabinoidReceptorNeuroscienceAnesthesiaInternal medicinePsychologyElectroencephalogramEndocannabinoid SystemPositive Allosteric ModulatorChildhood Absence EpilepsyGaersType 1 Cannabinoid ReceptorEeg, Electroencephalography2-Ag, 2-ArachidonoylglycerolAea, AnandamideEcs, Endocannabinoid SystemLfp, Local Field PotentialCae, Childhood Absence EpilepsyCb1r, Cannabinoid Type-1 ReceptorGaers, Genetic Absence Epilepsy Rats From StrasbourgPam, Positive Allosteric ModulatorSwd, Spike And Wave DischargeThc, Δ9-tetrahydrocannabinolAgo-pam, Allosteric Agonist And Positive Allosteric ModulatorNeurosciences. Biological psychiatry. NeuropsychiatryArticleRC321-571

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

The type 1 cannabinoid receptor positive allosteric modulators GAT591 and GAT593 reduce spike-and-wave discharges in Genetic Absence Epilepsy Rats from Strasbourg

FAIR Checklist

Authors (11)

Funding (7 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)